"Netherlands Pharmaceuticals & Healthcare Report Q3 2016" now available at Fast Market Research

The Netherlands has a well establish pharmaceutical and healthcare sector . In 2016, the pharmaceutical market will face yet another year of contraction in value terms before returning to growth in 2017. Medicine sales will be driven by an ageing population and high per capita spending, ensuring the demand for prescription medicines remain s high. However, despite an improvement in economic conditions, the rising cost of healthcare will put considerable pressure on the government to implement further cost-efficiencies.

Headline Expenditure Projections

Full Report Details at
- http://www.fastmr.com/prod/1197535_netherlands_pharmaceuticals.aspx?afid=301

Pharmaceuticals: EUR5.82bn (USD6.45bn) in 2015 to EUR5.80bn (USD6.20bn) in 2016; -0.4% in local currency terms and -3.9% in US dollar terms. Forecast in line with last quarter.

Healthcare: EUR72.78bn (USD80.72bn) in 2015 to EUR73.72bn (USD78.89bn) in 2016; +1.3% in local currency terms and -2.3% in US dollar terms. Forecast revised downwards from last quarter.

Risk/Reward Index

The Netherlands continues to rank in the lower half of BMI's Risk/Reward Index (RRI) for the 15 key Western European markets, ranking 11th in our index for Q316. At 70.6, the country's overall RRI score marginally improves from last quarter (70.2) and is in line with the regional average. The country offers drugmakers a relatively low-risk operating environment among a high pensionable population (a score of 8.0 out of 8). However poor market prospects (Sector Value Growth score of 4.8 out of 12) - due to pressures on pricing and reimbursement and the market's maturity - will continue to weigh on the country's overall standing.

Latest Updates

In May 2016, Netherlands-based Mylan announced its plans to acquire a dermatology drug business from Illinois pharmaceutical company Renaissance Acquisition Holdings for up to USD1bn by September this year.

According to the Dutch Euthanasia Commission, the number of Dutch citizens who end their lives by euthanasia rose by 75% in the past five years from 3,136 in 2010 to 5,516 in 2015 with experts particularly concerned by a sharp rise in cases for psychiatric reasons.

In May 2016, new figures released by the National Statics Office calculated that healthcare in the Netherlands reached a value of EUR5,228 (USD5,855) per person in 2015.

In April 2016, the NRC found that Dutch health insurance companies are making losses on basic policies due to low charging of premiums, with the four market leaders spending a combined EUR1.8bn (USD2.0bn) or 5.0% of their turnover on subsidising cheap policies in 2015.

BMI Economic View

Real GDP growth in the Netherlands in 2016 will be driven mainly by domestic demand, bolstered by a fiscal stimulus package, and a sustained recovery in the housing market. We forecast real GDP growth of 2.0% in 2016, marking a modest acceleration from the growth outturn of 1.9% in 2015.

BMI Political View

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Qatar Pharmaceuticals & Healthcare Report Q3 2016
- Turkey Pharmaceuticals & Healthcare Report Q3 2016
- Brazil Pharmaceuticals & Healthcare Report Q3 2016
- Czech Republic Pharmaceuticals & Healthcare Report Q3 2016
- United Arab Emirates Pharmaceuticals & Healthcare Report Q3 2016